{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:20:01Z","timestamp":1789150801331,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40272-026-00747-4","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:06:26Z","timestamp":1775135186000},"page":"307-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"28","clinical-trial-number":[{"clinical-trial-number":"nct02612454","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03346434","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Wine Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Aschoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Zdybski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Schnopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal A.","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy H.","family":"Praestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Shumel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8347-7426","authenticated-orcid":false,"given":"Mike","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"1","key":"747_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. https:\/\/doi.org\/10.1038\/s41572-018-0001-z.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"747_CR2","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jaad.2024.10.107","volume":"92","author":"UE Choi","year":"2025","unstructured":"Choi UE, Deng J, Parthasarathy V, Liao V, D\u2019Amiano A, Taylor M, et al. Risk factors and temporal associations of progression of the atopic march in children with early-onset atopic dermatitis. J Am Acad Dermatol. 2025;92(4):732\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2024.10.107.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"747_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/ddg.15344","volume":"22","author":"AB Weins","year":"2024","unstructured":"Weins AB, Kerzel S, Schnopp C. Severe atopic dermatitis in early infancy: characteristics, challenges and new perspectives in clinical practice. JDDG. 2024;22(3):350\u20135. https:\/\/doi.org\/10.1111\/ddg.15344.","journal-title":"JDDG"},{"issue":"4","key":"747_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-28.e2. https:\/\/doi.org\/10.1016\/j.anai.2020.12.020.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"747_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.36849\/JDD.6408","volume":"21","author":"R Chovatiya","year":"2022","unstructured":"Chovatiya R, Silverberg JI. The heterogeneity of atopic dermatitis. J Drugs Dermatol. 2022;21(2):172\u20136. https:\/\/doi.org\/10.36849\/JDD.6408.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"747_CR6","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/jdv.13689","volume":"30","author":"JG Holm","year":"2016","unstructured":"Holm JG, Agner T, Clausen M-L, Thomsen SF. Quality of life and disease severity in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2016;30(10):1760\u20137. https:\/\/doi.org\/10.1111\/jdv.13689.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"747_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jpeds.2022.04.027","volume":"246","author":"S Barbarot","year":"2022","unstructured":"Barbarot S, Silverberg JI, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study. J Pediatr. 2022;246:220-6.e5. https:\/\/doi.org\/10.1016\/j.jpeds.2022.04.027.","journal-title":"J Pediatr"},{"issue":"4","key":"747_CR8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","volume":"77","author":"EL Simpson","year":"2017","unstructured":"Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623\u201333. https:\/\/doi.org\/10.1016\/j.jaad.2017.06.042.","journal-title":"J Am Acad Dermatol"},{"key":"747_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/CCID.S163814","volume":"12","author":"BB Johnson","year":"2019","unstructured":"Johnson BB, Franco AI, Beck LA, Prezzano JC. Treatment-resistant atopic dermatitis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:181\u201392. https:\/\/doi.org\/10.2147\/CCID.S163814.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"11","key":"747_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.5694\/mja2.51560","volume":"216","author":"MSY Goh","year":"2022","unstructured":"Goh MSY, Yun JSW, Su JC. Management of atopic dermatitis: a narrative review. Med J Aust. 2022;216(11):587\u201393. https:\/\/doi.org\/10.5694\/mja2.51560.","journal-title":"Med J Aust"},{"issue":"6","key":"747_CR11","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.14888","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378. https:\/\/doi.org\/10.1111\/jdv.14888.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"747_CR12","unstructured":"S3-Leitlinie: Atopische Dermatitis. AWMF-Registernr. 013-027. 2023. https:\/\/register.awmf.org\/assets\/guidelines\/013-027l_S3_Atopische-Dermatitis-AD-Neurodermitis-atopisches-Ekzem_2024-01.pdf. Accessed 1 Oct 2025."},{"key":"747_CR13","unstructured":"European Medicines Agency. Dupixent. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dupixent. Accessed 1 Oct 2025."},{"key":"747_CR14","unstructured":"Regeneron Pharmaceuticals Inc. Dupixent Highlights of Prescribing Information. https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf. Accessed 1 Oct 2025."},{"issue":"10356","key":"747_CR15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(22)01539-2.","journal-title":"Lancet"},{"issue":"4","key":"747_CR16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"25","author":"AS Paller","year":"2024","unstructured":"Paller AS, Siegfried EC, Simpson EL, Cork MJ, Sidbury R, Chen IH, et al. Dupilumab safety and efficacy up to 1 year in children aged 6 months to 5 years with atopic dermatitis: results from a phase 3 open-label extension study. Am J Clin Dermatol. 2024;25(4):655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(22)01539-2.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"747_CR17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s12325-023-02753-1","volume":"41","author":"AS Paller","year":"2024","unstructured":"Paller AS, Pinter A, Wine Lee L, Aschoff R, Zdybski J, Schnopp C, et al. Efficacy and safety of dupilumab treatment with concomitant topical corticosteroids in children aged 6 months to 5 years with severe atopic dermatitis. Adv Ther. 2024;41(3):1046\u201361. https:\/\/doi.org\/10.1007\/s12325-023-02753-1.","journal-title":"Adv Ther"},{"issue":"11","key":"747_CR18","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1007\/s13555-023-01016-9","volume":"13","author":"MJ Cork","year":"2023","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, Arkwright PD, Chen Z, Thomas RB, et al. Dupilumab safety and efficacy in a phase III open-label extension trial in children 6-11 years of age with severe atopic dermatitis. Dermatol Ther. 2023;13(11):2697\u2013719. https:\/\/doi.org\/10.1007\/s13555-023-01016-9.","journal-title":"Dermatol Ther"},{"issue":"3","key":"747_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","volume":"23","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365\u201383. https:\/\/doi.org\/10.1007\/s40257-022-00683-2.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"747_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","volume":"82","author":"M Deleuran","year":"2020","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377\u201388. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.074.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"747_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40272-023-00611-9","volume":"26","author":"AS Paller","year":"2024","unstructured":"Paller AS, Siegfried EC, Cork MJ, Arkwright PD, Eichenfield LF, Ramien M, et al. Infections in children aged 6 months to 5 years treated with dupilumab in a placebo-controlled clinical trial of moderate-to-severe atopic dermatitis. Paediatr Drugs. 2024;26(2):163\u201373. https:\/\/doi.org\/10.1007\/s40272-023-00611-9.","journal-title":"Paediatr Drugs"},{"issue":"3","key":"747_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12016-016-8548-5","volume":"51","author":"PY Ong","year":"2016","unstructured":"Ong PY, Leung DYM. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;51(3):329\u201337. https:\/\/doi.org\/10.1007\/s12016-016-8548-5.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"747_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/pde.15781","volume":"42","author":"AS Paller","year":"2025","unstructured":"Paller AS, Ramien M, Cork MJ, Simpson EL, Wine Lee L, Eichenfield LF, et al. Low infection rates with long-term dupilumab treatment in patients aged 6 months to 5 years: an open-label extension study. Pediatr Dermatol. 2025;42(2):251\u20138. https:\/\/doi.org\/10.1111\/pde.15781.","journal-title":"Pediatr Dermatol"},{"issue":"10","key":"747_CR24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/j.1610-0387.2007.06488.x","volume":"5","author":"AK Kienast","year":"2007","unstructured":"Kienast AK, Kreth HW, H\u00f6ger PH. Varicella vaccination in children with atopic eczema. JDDG. 2007;5(10):875\u201380. https:\/\/doi.org\/10.1111\/j.1610-0387.2007.06488.x.","journal-title":"JDDG"},{"key":"747_CR25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00431-006-0103-6","volume":"165","author":"HW Kreth","year":"2006","unstructured":"Kreth HW, H\u00f6ger PH, et al. Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. Eur J Pediatr. 2006;165:677\u201383. https:\/\/doi.org\/10.1007\/s00431-006-0103-6.","journal-title":"Eur J Pediatr"},{"key":"747_CR26","unstructured":"DUPIXENT\u00ae (dupilumab). Highlights of prescribing information. Accessed 28 Jan 2026. https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00747-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00747-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00747-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:48:44Z","timestamp":1777286924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00747-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["747"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00747-4","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amy S. Paller has served as investigator for AbbVie, BioMendics, Dermavant, Eli Lilly, Incyte, Johnson & Johnson Innovative Medicine, Regeneron Pharmaceuticals Inc., and UCB; consultant for Abeona, Arcutis, BioCryst, Boehringer Ingelheim, Castle Creek, Chiesi, Dermavant, Johnson & Johnson Innovative Medicine, Krystal, LEO, Lilly, L\u2019Or\u00e9al, MoonLake Immunotherapeutics, Pelthos, Quoin, Regeneron Pharmaceuticals Inc., and Sanofi; and as a data safety monitoring board member for AbbVie, Abeona, BioCryst, Daiichi Sankyo, and Galderma. Andreas Pinter has conducted clinical trials for AbbVie, Almirall Hermal, Amgen, Biogen Idec, BioNTech, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Galderma, GSK, Hexal, Janssen, Klinge Pharma, LEO Pharma, MC2 Pharma, Medac, Merck Serono, Mitsubishi Tanabe Pharma, MSD, Novartis, Pascoe, Pfizer, Regeneron Pharmaceuticals Inc., Roche, Sandoz, Sanofi, Schering-Plough, Tigercat Pharma, UCB Pharma, and Zuellig Pharma; received speaker fees from AbbVie, Almirall Hermal, Amgen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Galderma, Janssen, Klinge Pharma, LEO Pharma, Medac, Novartis, Pfizer, Sanofi, UCB Pharma, and Zuellig Pharma; and grants from AbbVie and Almirall. Lara Wine Lee has served as an advisory board member for Castle Creek Biosciences, Chiesi, Eli Lilly, Pfizer, Regeneron Pharmaceuticals Inc., TWi Biotechnology, and Verrica; consultant for AbbVie, Apogee, Chiesi, Eli Lilly, Kimberly-Clark, Krystal Biotech, and Novartis; investigator for AbbVie, Amgen, Amryt Pharma, Apogee, Arcutis Biotherapeutics, Boehringer Ingelheim, Castle Creek Biosciences, Celgene, Eli Lilly, Galderma, Incyte, LEO Pharma, Mayne Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Target Pharma, Trevi Therapeutics, TWi Biotechnology, and UCB; speaker for Chiesi, Krystal Biotech, and Sanofi; and as a data safety monitoring board member for BMS. Ronald Aschoff has been a speaker for AbbVie, Almirall Hermal, Biofrontera, BMS, Boehringer Ingelheim, BSN medical, Galderma, Incyte, Janssen-Cilag, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB; and a consultant with honorarium for Almirall Hermal, Janssen-Cilag, and LEO Pharma. Jacek Zdybski served as an investigator for Almirall, Amgen, BMS, Galderma, Incyte, Innovaderm, Pfizer, Regeneron Pharmaceuticals Inc., and Syneos Health. Christina Schnopp has conducted clinical studies for Benevi, Novartis, and Sanofi; has been a lecturer at educational events for AbbVie, Amgen, Galderma, InfectoPharm, La Roche-Posay, LEO Pharma, LETI Pharma, Lilly, MSD, Nestl\u00e9, Novartis, and Pierre Fabre; and has served as a consultant for Lilly, Novartis, Pierre Fabre, and Sanofi. Faisal A. Khokhar, Ashish Bansal, and Brad Shumel are employees and shareholders of Regeneron Pharmaceuticals Inc. Amy H. Praestgaard and Mike Bastian are employees of and may hold stock and\/or stock options in Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing 1) once the product and indication has been approved by major health authorities (e.g., FDA, EMA, PMDA) or development of the product has been discontinued globally for all indications on or after April 2020 and there are no plans for future development; 2) if there is legal authority to share the data; and 3) there is not a reasonable likelihood of participant re-identification. Submit requests to\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guideline, and applicable regulatory requirements. An independent data and safety monitoring committee conducted blinded monitoring of patient safety data. The local institutional review board (IRB) or ethics committee (EC) at each study center oversaw trial conduct and documentation. A list of IRB\/EC approval numbers for each participating site is provided in the Supplementary Information (Appendix S2).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All patients, or their parents\/guardians, provided written informed consent before participating in the trial. Pediatric patients provided assent according to the ethics committee (institutional review board\/independent ethics committee)-approved standard practice for pediatric patients at each participating center.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Mike Bastian, Brad Shumel, and Ashish Bansal designed the study. Amy Paller, Andreas Pinter, Lara Wine Lee, Roland Aschoff, Jacek Zdybski, and Christina Schnopp acquired data. Amy Praestgaard conducted the statistical analyses of the data. All authors interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and are accountable for the accuracy and integrity of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}